Anna Franzone

Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy

Roberta Roncarati, Chiara Viviani Anselmi, Maria Angela Losi et al. · Journal of the American College of Cardiology · 2013 · 318 citations · Full text

Cardiomyopathy, Heart Failure, Both Hypertrophy +9

Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

Anna Franzone, Eugène McFadden, Sergio Leonardi et al. · Journal of the American College of Cardiology · 2019 · 145 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +10

Frequency, Timing, and Impact of Access-Site and Non–Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement

Raffaele Piccolo, Thomas Pilgrim, Anna Franzone et al. · JACC: Cardiovascular Interventions · 2017 · 143 citations

Cardiovascular Disease, Non–access-site Bleeding, Patient Safety +10

Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial

Roberto Galea, Federico De Marco, Nicolas Méneveau et al. · Circulation · 2021 · 131 citations · Full text

Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement

Masahiko Asami, Stefan Stortecky, Fabien Praz et al. · JACC. Cardiovascular imaging · 2018 · 117 citations

Right Ventricular Dysfunction, Heart Failure, Cardiovascular Disease +11